betaSENSE products
betaSENSE - Infrared Spectroscopy Platform Technology for Early Detection of Neurodegenerative Diseases
betaSENSE has developed a cutting-edge platform technology leveraging the principles of infrared spectroscopy to advance diagnostics in neurodegenerative disorders. The technology, known as betaSENSE, utilizes differential spectroscopy to detect minute changes between states of a sample by subtracting absorption spectra, thereby highlighting protein signals such as amyloid-beta and alpha-synuclein on functionalized biochips. This approach allows differentiation of protein secondary structures by their unique infrared absorption characteristics, aiding in early detection of diseases like Alzheimer's and Parkinson's. The technology facilitates early intervention by identifying amyloid-beta deposits linked to Alzheimer's well before symptomatic onset, using specific antibodies to study extracted proteins. Similarly, in Parkinson's disease, the platform detects misfolded alpha-synuclein proteins that form Lewy bodies. The platform supports the pharmaceutical research in drug discovery and clinical studies, offering reliable risk stratification of participants. Being rigorously tested, this platform represents a significant step in precision medicine, aimed at altering the progression of neurodegenerative diseases.betaSENSE - iRS Technology for Parkinson's Diagnosis
The advancement of the iRS technology from betaSENSE represents a significant innovation in the field of Parkinson's disease diagnostics. This technology addresses the critical unmet medical needs in accurately diagnosing Parkinson's and distinguishing between idiopathic and atypical cases. While there have been notable improvements in Parkinson's treatment, existing therapies often fall short, particularly in addressing non-motor symptoms such as cognitive impairments, depression, and autonomic dysregulations. iRS technology enhances diagnostic precision by identifying specific biomarkers, namely alpha-synuclein misfolding, involved in Parkinson's and related synucleinopathies. This method paves the way for future use in early detection and patient stratification, potentially supporting the development of disease-modifying therapies that could slow or halt disease progression. As a spin-off from Ruhr University Bochum, betaSENSE is at the forefront of certified diagnostic technology innovation, working to improve outcomes for individuals affected by Parkinson's.